PharVision Advisers’s Textron TXT Stock Holding History

PharVision Advisers’s Portfolio TXT Stock Details TXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,121	Closed	-$348K	–	1017
2025 Q3	$348K	Buy	+4,121	New	+$336K	0.2%	141

Other funds holding TXT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

PharVision Advisers's TXT Position: Q4 2025 in Review

PharVision Advisers sold out of Textron (TXT) in Q4 2025, closing a stake of 4,121 shares — an estimated $348K sold.

PharVision Advisers first reported a position in TXT in Q3 2025 and held it in 1 quarter. The position peaked at $348K in Q3 2025. 756 funds tracked by Wall St. Rank hold TXT as of Q4 2025.

PharVision Advisers reported no remaining Textron position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 4,121 Textron shares in Q4 2025, an estimated $348K.
PharVision Advisers first reported a position in Textron in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Textron position peaked at $348K in Q3 2025.
756 funds tracked by Wall St. Rank held Textron as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.